Although rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-
CHOP) is the standard treatment for patients with diffuse large B-cell lymphoma (DLBCL),∼ …

Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoid malignancy in adults
accounting for 31% of all NHL in Western Countries. Following, morphological, biological …

The purpose of this work was to modernize recommendations for evaluation, staging, and
response assessment of patients with Hodgkin lymphoma (HL) and non-Hodgkin lymphoma …

Purpose Recent advances in imaging, use of prognostic indices, and molecular profiling
techniques have the potential to improve disease characterization and outcomes in …

Abstract PET using 18 F-FDG for treatment monitoring in patients with lymphoma is one of
the most well-developed clinical applications. PET/CT is nowadays used during treatment to …

Background The study objectives were to assess the prognostic value of quantitative PET
and to test whether combining baseline metabolic tumour burden with early PET response …

Accurate prediction of long-term outcomes remains a challenge in the care of cancer
patients. Due to the difficulty of serial tumor sampling, previous prediction tools have focused …

Since its introduction in the early nineties as a promising functional imaging technique in the
management of neoplastic disorders, FDG-PET, and subsequently FDG-PET/CT, has …

Purpose The role of interim PET/CT in guiding therapeutic strategies in diffuse large B-cell
lymphoma (DLBCL) is debated, mainly because interpretation rules vary among centres …

1Department of Haematology, Queen Elizabeth Hospital, Birmingham, 2Department of
Clinical Oncology, Christie Hospital, Manchester, 3PET Imaging Centre, King's College …